Literature DB >> 29150897

Determining best outcomes from community-acquired pneumonia and how to achieve them.

Jane Hadfield1, Lesley Bennett1.   

Abstract

Community-acquired pneumonia (CAP) is a common acute medical illness with a standard, effective treatment that was introduced before the evidenced-based medicine era. Mortality rates have improved in recent decades but improvements have been minimal when compared to other conditions such as acute coronary syndromes. The standardized approach to treatment makes CAP a target for comparative performance and outcome measures. While easy to collect, simplistic outcomes such as mortality, readmission and length of stay are difficult to interpret as they can be affected by subjective choices and health care resources. Proposed clinical- and patient-reported outcomes are discussed below and include measures such as the time to clinical stability (TTCS) and patient satisfaction, which can be compared between health institutions. Strategies to improve these outcomes include use of a risk stratification tool, local antimicrobial guidelines with antibiotic stewardship and care bundles to include early administration of antibiotics and early mobilization.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  antibiotics; guidelines; mortality; outcomes; pneumonia

Mesh:

Substances:

Year:  2017        PMID: 29150897     DOI: 10.1111/resp.13218

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Authors:  Thomas P Lodise; Sam Colman; Elizabeth Alexander; Daniel S Stein; David Fitts; Lisa Goldberg; Jennifer Schranz
Journal:  Open Forum Infect Dis       Date:  2020-06-03       Impact factor: 3.835

2.  Patient-reported outcome measures in community-acquired pneumonia: a systematic review of application and content validity.

Authors:  Melanie Lloyd; Emily Callander; Amalia Karahalios; Lucy Desmond; Harin Karunajeewa
Journal:  BMJ Open Respir Res       Date:  2019-06-02

Review 3.  Contemporary Concise Review 2018: Respiratory infections and tuberculosis.

Authors:  David S Hui; Chi-Chiu Leung
Journal:  Respirology       Date:  2019-03-30       Impact factor: 6.424

4.  Respiratory infections in the Asia-Pacific region: Problems and cautious optimism.

Authors:  Grant Waterer
Journal:  Respirology       Date:  2017-12-21       Impact factor: 6.424

Review 5.  Updates on community acquired pneumonia management in the ICU.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Pharmacol Ther       Date:  2020-08-15       Impact factor: 12.310

6.  Early mobilisation of patients with community-acquired pneumonia reduce length of hospitalisation-a pilot study.

Authors:  Dorte Melgaard; Ulrik Baandrup; Martin Bøgsted; Mette Dahl Bendtsen; Morten Tange Kristensen
Journal:  J Phys Ther Sci       Date:  2018-07-03

7.  Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population.

Authors:  Melanie A Lloyd; Clarice Y Tang; Emily J Callander; Edward D Janus; Amalia Karahalios; Elizabeth H Skinner; Stephanie Lowe; Harin A Karunajeewa
Journal:  Pilot Feasibility Stud       Date:  2019-07-27

Review 8.  Community-Acquired Pneumonia.

Authors:  Ashley C Rider; Bradley W Frazee
Journal:  Emerg Med Clin North Am       Date:  2018-09-06       Impact factor: 2.264

9.  Empirical prescribing of penicillin G/V reduces risk of readmission of hospitalized patients with community-acquired pneumonia in Norway: a retrospective observational study.

Authors:  June Utnes Høgli; Beate Hennie Garcia; Kristian Svendsen; Vegard Skogen; Lars Småbrekke
Journal:  BMC Pulm Med       Date:  2020-06-15       Impact factor: 3.317

Review 10.  Challenges in severe community-acquired pneumonia: a point-of-view review.

Authors:  Antoni Torres; James D Chalmers; Charles S Dela Cruz; Cristina Dominedò; Marin Kollef; Ignacio Martin-Loeches; Michael Niederman; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2019-01-31       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.